BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11439034)

  • 1. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.
    Zewail-Foote M; Hurley LH
    J Am Chem Soc; 2001 Jul; 123(27):6485-95. PubMed ID: 11439034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
    Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
    Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
    Hurley LH; Zewail-Foote M
    Adv Exp Med Biol; 2001; 500():289-99. PubMed ID: 11764956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.
    Zewail-Foote M; Hurley LH
    J Med Chem; 1999 Jul; 42(14):2493-7. PubMed ID: 10411470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
    Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
    Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.
    Marco E; García-Nieto R; Mendieta J; Manzanares I; Cuevas C; Gago F
    J Med Chem; 2002 Feb; 45(4):871-80. PubMed ID: 11831898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
    Marco E; David-Cordonnier MH; Bailly C; Cuevas C; Gago F
    J Med Chem; 2006 Nov; 49(23):6925-9. PubMed ID: 17154523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
    Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulative interplay of two adozelesin molecules with d(ATTAAT)₂achieving ligand-stacked Watson-Crick and Hoogsteen base-paired duplex adducts.
    Hopton SR; Thompson AS
    Biochemistry; 2011 May; 50(19):4143-54. PubMed ID: 21469674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands.
    Marco E; Gago F
    Mol Pharmacol; 2005 Dec; 68(6):1559-67. PubMed ID: 16150929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
    Aune GJ; Furuta T; Pommier Y
    Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
    García-Nieto R; Manzanares I; Cuevas C; Gago F
    J Med Chem; 2000 Nov; 43(23):4367-9. PubMed ID: 11087561
    [No Abstract]   [Full Text] [Related]  

  • 13. The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
    Sainz-Diaz CI; Manzanares I; Francesch A; Garcia-Ruiz J
    Acta Crystallogr C; 2003 Apr; 59(Pt 4):O197-8. PubMed ID: 12682407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
    Martinez EJ; Owa T; Schreiber SL; Corey EJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3496-501. PubMed ID: 10097064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a common molecular basis for sequence recognition of N3-guanine and N3-adenine DNA adducts involving the covalent bonding reaction of (+)-CC-1065.
    Park HJ
    Arch Pharm Res; 2002 Feb; 25(1):11-24. PubMed ID: 11885687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
    Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
    Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular topology of polycyclic aromatic carcinogens determines DNA adduct conformation: a link to tumorigenic activity.
    Lin CH; Huang X; Kolbanovskii A; Hingerty BE; Amin S; Broyde S; Geacintov NE; Patel DJ
    J Mol Biol; 2001 Mar; 306(5):1059-80. PubMed ID: 11237618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.
    Bonfanti M; La Valle E; Fernandez Sousa Faro JM; Faircloth G; Caretti G; Mantovani R; D'Incalci M
    Anticancer Drug Des; 1999 Jun; 14(3):179-86. PubMed ID: 10500494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
    Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.